D9319C00001- 1L OC Mono Global RCT
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Overview
D9319C00001- 1L OC Mono Global RCT is a phase 3 interventional study registered as NCT04884360 by AstraZeneca, with 366 participants enrolled, started 2021-05-31 and due to reach its primary completion in 2026-07-27. Interventions recorded: Olaparib, Matching placebo. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)
Phase
Phase 3
Sponsor
AstraZeneca
Registry
Enrolled
366
Similar pages
not linked directly; found by shared links- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Olaparib, AstraZeneca, Ovarian cancer.
- TrialWoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Shares Olaparib, Ovarian cancer.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, AstraZeneca.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, AstraZeneca.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, AstraZeneca.
- TrialStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Shares Olaparib, AstraZeneca.